Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2Review Article Published on 2021-05-132022-10-30 Journal: NPJ Vaccines [Category] COVID-19, [키워드] Adaptive immunity adverse events Antibody binding BNT162b2 Comparative Efficacy ELISPOT emergence Frequency functional highest Infectious diseases literature review Meta-analysis Mild mRNA vaccine mRNA-1273 NAb neutralizing antibody NHP non-human primate phase reactogenicity reduce response responses SARS-CoV-2 SARS-CoV-2 vaccine selective systematic review T cell trade-off Trial vaccination Vaccine vaccine platform Vaccines variant Viral vector [DOI] 10.1038/s41541-021-00336-1 PMC 바로가기 [Article Type] Review Article
Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient SurveyBrief Report Published on 2021-03-172022-10-29 Journal: International Review of Cell and Molecular Biology [Category] COVID-19, [키워드] 95% confidence interval adverse events anaphylaxis breathlessness Care conducted Coronavirus disease 2019 COVID-19 COVID-19 illness COVID-19 infection COVID-19 vaccine dose eligible fatigue Fever groups hospital incidence increased risk less Local local reaction mRNA vaccine randomised controlled trial RCTs Reactions reactogenicity recipient reported risk Safe Safety severity Side effect Side effects survey systemic reaction systemic side effect Tolerability vaccination Vaccines viral vector-based were assessed while [DOI] 10.3390/life11030249 PMC 바로가기 [Article Type] Brief Report
Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 InfectionSARS-CoV-2 감염 이전에 BNT162b2 mRNA COVID-19 백신에 대한 항체 반응Clinical Trial Published on 2021-03-052022-08-13 Journal: Viruses [Category] SARS, 임상, 진단, [키워드] all subject all subjects analyzed Anti-spike anti-spike RBD IgG antibody antibody antibody levels Antibody Response Antibody titers BNT162b2 BNT162b2 mRNA BNT162b2 mRNA COVID-19 vaccine booster both groups control subject COVID-19 COVID-19 vaccine COVID-19 vaccines decrease develop domain effective response expected first dose Frequency healthcare worker IgG antibodies IgG antibody immune memory immune memory persist immune response immunogenicity individual induce infected individuals Infection local pain naïve individuals naïve subject naïve subjects natural infection Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers nine no significant difference not significantly different pre-existing immunity rapid increase RBD reactogenicity response SARS-CoV-2 SARS-COV-2 infection Side effects single dose subjects sustained the antibody response the vaccine titers vaccination Vaccine vaccine dose vaccine doses vaccine-associated side effects [DOI] 10.3390/v13030422 PMC 바로가기 [Article Type] Clinical Trial
Nanomaterial Delivery Systems for mRNA VaccinesReview Published on 2021-01-192022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] adjuvant Analysis clinical trial clinical trials delivery determinant Express Intramuscular injection Ionizable lipid Lipid nanoparticle mRNA mRNA vaccine mRNA vaccines reactogenicity SARS-CoV-2 SARS-CoV-2 vaccine System Vaccine [DOI] 10.3390/vaccines9010065 PMC 바로가기 [Article Type] Review
Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging PathogensImmunology Published on 2021-01-082022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS, [키워드] accelerated Against age Antigen caused clinical observation clinical trial clinical trials co-morbidity COVID-19 development difference Diseases Ebola virus disease Effect Effectiveness Efficacy emerging infections Epidemics Evidence Factor Genetic highlight Hormones immune implementation implication individual infections investigated lack limit mechanism mechanisms Microbiome miRNAs novel Outbreaks outcome pandemic public health reactogenicity regimen response response to vaccination resulting review Sex Sex difference sex differences tested the SARS-CoV-2 undergo vaccination Vaccine vaccine candidate Vaccine development Vaccines West X-chromosome inactivation X-linked gene products [DOI] 10.3389/fimmu.2020.601170 PMC 바로가기 [Article Type] Immunology
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineClinical Trial Published on 2020-12-302022-10-04 Journal: The New England Journal of Medicine [Category] MERS, SARS, 임상, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome adverse event age Analysis Aside assigned authority baseline cause Complication complications conducted coronavirus coronavirus disease development Efficacy ENCODE enrolled Evidence first dose full-length spike protein high risk incidence infected with SARS-CoV-2 injection Injections Intramuscular injection Local mRNA-1273 mRNA-1273 vaccine mRNA-based vaccine observer-blinded occurred Older participant Participants Person Phase 3 Placebo placebo-controlled trial prefusion Prevent primary end point PROTECT Randomized Randomly reactogenicity receive Result Safety SARS-CoV-2 SARS-COV-2 infection Secondary analyses severe disease systemic reactions the placebo group The United States Trial two groups vaccination Vaccine virus Volunteer [DOI] 10.1056/NEJMoa2035389 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 RBD Neutralizing Antibody Induction is Enhanced by Particulate VaccinationSARS-CoV-2 RBD 중화 항체 유도는 미립자 백신 접종으로 강화됩니다Article Published on 2020-12-012022-09-12 Journal: Advanced Materials (Deerfield Beach, Fla.) [Category] MERS, SARS, 진단, [키워드] accounted ACE2 angiotensin-converting enzyme 2 Antibody Response Antibody titer Antigen antigen binding antigen-presenting cell antigens bind candidate vaccine cell entry COVID-19 domain draining lymph nodes ENhance enhanced functional greater High dose Immune cell infiltration immunization immunization result Inclusion induce induction inhibit insertion Interaction Liposome liposomes Live virus Local magnitude mice Nanoparticles neutralize Neutralizing antibody response Particulate pseudovirus QS-21 RBD reactogenicity Replication SARS-CoV-2 SARS-CoV-2 RBD serum shown Spike protein T cell response the RBD the SARS-CoV-2 Vaccine Vaccines virus entry [DOI] 10.1002/adma.202005637 PMC 바로가기 [Article Type] Article
MPL Adjuvant Contains Competitive Antagonists of Human TLR4Original Research Published on 2020-10-162024-09-02 Journal: Frontiers in immunology [Category] 대상포진, [키워드] monophosphoryl lipid A (MPL) partial agonist reactogenicity Safety Toll-like receptor 4 (TLR4) vaccine adjuvant [DOI] 10.3389/fimmu.2020.577823 PMC 바로가기 [Article Type] Original Research
Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study건강한 러시아 참가자에게 추가 백신 용량으로 투여된 항원 함량이 감소된 디프테리아-파상풍-무세포 백일해 혼합 백신의 면역원성, 안전성 및 반응성: 제3상 공개 라벨 연구Research Article Published on 2020-08-262024-07-28 Journal: Human vaccines & immunotherapeutics [Category] 백일해, 파상풍, [키워드] acellular pertussis booster vaccination Diphtheria immunogenicity reactogenicity Safety Tetanus [DOI] 10.1080/21645515.2020.1796423 PMC 바로가기 [Article Type] Research Article
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults Research Published on 2020-08-122022-10-05 Journal: Nature [Category] 유전자 메커니즘, 임상, [키워드] accumulating acute respiratory syndrome Administered age BNT162b1 caused Concentration convalescent coronavirus coronavirus disease COVID-19 death domain dose dose-dependent dose-escalation ENCODE event generally mild geometric mean healthy human sera immunogenicity data Increased immunogenicity lack local reaction moderate mRNA vaccine Neutralizing nucleoside-modified mRNA observer-blinded pandemic placebo-controlled positive SARS-CoV-2 PCR Randomized RBD RBD-binding IgG reached reactogenicity receive reported RNA vaccine SARS-CoV-2 second dose second vaccination sera single dose spike glycoprotein Support titre Tolerability Vaccine WHO World Health Organization [DOI] 10.1038/s41586-020-2639-4 [Article Type] Research